Minted: - / 5000

1387 Relamorelin
aa6f1a29501e1cabfa4a0931b674f9ceb14abe79a4919a741cf672302426a3b5

Properties

Background

Brown
Bottle

Purple
Cap

Orange
Syringe

Green
Bubbles
No
Drops
Yes
Label
Bacterium

Chemistry

Formula
C43H50N8O5S
Carbon
43
Polarity
Neutral

Relamorelin (INN, USAN) (developmental code names RM-131, BIM-28131, BIM-28163) is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) which is under development by Allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. It is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics. In humans, relamorelin produces increases in plasma growth hormone, prolactin, and cortisol levels, and, like other GHSR agonists, increases appetite. As of June 2015, relamorelin is in phase II clinical trials for diabetic gastroparesis and constipation. The United States Food and Drug Administration (FDA) has granted Fast Track designation to relamorelin for diabetic gastroparesis.

From Wikipedia, the free encyclopedia. License: CC BY-SA.